Not medical advice. Talk to your provider before using any peptide. Full disclaimer
Lipo-C
Also known as: MIC injection, lipotropic injection, Lipo-C MIC
Thirty-seven randomized controlled trials on L-carnitine alone. Zero on the Lipo-C combination itself. That gap tells you exactly where this product sits in 2026. Lipo-C is a compounded injection containing six ingredients (Methionine, Inositol, Choline, L-Carnitine, Thiamine, Dexpanthenol) that each play a documented role in hepatic fat processing. Weight loss clinics pair it with GLP-1 agonists like semaglutide to offset energy deficits during aggressive caloric restriction. Community reports consistently confirm the energy boost from B vitamins. Fat loss without a caloric deficit? Both the research and thousands of user reports agree: that doesn't happen.
What Is Lipo-C?
Lipo-C (also called lipotropic MIC injection) is a compounded blend of Methionine 15 mg, Inositol 50 mg, Choline Chloride 50 mg, L-Carnitine 50 mg, Thiamine 15 mg, and Dexpanthenol 5 mg per mL. It's not FDA-approved and not a single compound. It's a pharmacy-mixed cocktail of amino acids and B vitamins designed for metabolic support during caloric restriction.
The individual components have real mechanistic backing. L-carnitine shuttles long-chain fatty acids into mitochondria for beta-oxidation. A 2025 umbrella meta-analysis covering 16,352 participants across 8 meta-analyses [1] confirmed L-carnitine significantly reduces body weight (effect size -1.11 kg, p=0.005) and waist circumference (-1.34 cm, p<0.001). Choline is required for phosphatidylcholine synthesis and VLDL-mediated fat export from the liver; a 2025 RCT of 79 patients supports its role in hepatic steatosis.
The problem is that nobody has tested these six ingredients together in a controlled trial. All evidence is component-level. Weight loss telehealth clinics routinely prescribe Lipo-C alongside semaglutide or tirzepatide. Community experience across hundreds of reports on ExcelMale and r/peptides is consistent: energy improves within hours. Fat loss without a caloric deficit does not.
Lipo-C is best understood as metabolic support, not a primary intervention. The formulation arrives pre-mixed and requires no reconstitution, which lowers the barrier compared to lyophilized peptides. Standard dosing is 1 mL injected intramuscularly or subcutaneously, two to three times per week.
How Lipo-C Works
Six ingredients, six distinct metabolic contributions. Methionine donates methyl groups required for hepatic fat processing and is a precursor to S-adenosylmethionine (SAMe), which drives phospholipid synthesis. Inositol is a secondary messenger in insulin signaling pathways and assists in redistributing body fat away from the liver.
Choline is the rate-limiting nutrient for phosphatidylcholine production. Phosphatidylcholine is the primary phospholipid in VLDL particles, the liver's main vehicle for exporting triglycerides. Without adequate choline, fat accumulates in hepatic tissue. That connection is well established in nutritional biochemistry.
L-Carnitine handles the transport step. It shuttles long-chain fatty acids across the inner mitochondrial membrane through the carnitine palmitoyltransferase (CPT) system, enabling beta-oxidation. The 2025 umbrella meta-analysis [1] confirmed this translates to measurable, if modest, reductions in body weight and waist circumference across 16,352 pooled participants.
Thiamine (vitamin B1) and Dexpanthenol (provitamin B5) function as cofactors in the citric acid cycle and downstream energy metabolism pathways. Their contribution explains the 2 to 4 hour energy spike that users consistently report after injection. These are water-soluble vitamins; excess is excreted renally rather than stored.
The combined mechanism is additive rather than complementary. Each component acts through a separate pathway. No evidence supports any emergent property of the blend beyond what the individual ingredients provide separately.
Lipo-C Benefits
- Lipo-C benefits center on metabolic support and liver health during caloric restriction, not standalone fat loss.
- L-carnitine supplementation reduces body weight by a mean of 1.11 kg (p=0.005) and waist circumference by 1.34 cm (p<0.001) across 16,352 participants in 8 pooled meta-analyses [1].
- Energy boost from B-vitamin components (thiamine, dexpanthenol) is the most consistently reported benefit; community reports describe onset within 2 to 4 hours of injection, particularly useful during GLP-1-induced caloric restriction.
- Hepatic fat metabolism support through MIC (Methionine, Inositol, Choline) lipotropic agents; a 2025 RCT of 79 patients confirmed choline/phosphatidylcholine benefits for hepatic steatosis.
- Pre-mixed liquid formulation requires zero reconstitution, making it more accessible than lyophilized peptides for users new to injectable protocols.
- Stacks with GLP-1 agonists (semaglutide, tirzepatide) in clinical weight loss programs, providing energy maintenance on non-GLP-1 injection days.
Lipo-C: Science vs Community Consensus
No RCTs exist for the Lipo-C blend as a whole.
Read the evidence (key study, limitations)
Individual components have varying evidence: L-carnitine meta-analyses (2024–2025, n=16,352+) show modest but statistically significant weight/BMI reduction; a 2025 RCT (n=79) supports choline/phosphatidylcholine for hepatic steatosis; inositol has moderate evidence in PCOS. Combined injectable efficacy is unproven.
Umbrella meta-analysis 2025 (PMID 40298161): L-carnitine significantly reduces body weight (ES −1.11, p=0.005), BMI (−0.33, p=0.026), waist circumference (−1.34, p<0.001) across 8 meta-analyses, 16,352 participants. High heterogeneity (I²~90%): effect is real but modest.
Zero RCTs evaluate the Lipo-C combination formula specifically. All evidence is component-level. No large-scale RCT exists for IM/SC lipotropic MIC injections in humans. High heterogeneity limits generalizability of L-carnitine meta-analyses.
Broadly used as a metabolic support adjunct in clinical weight loss programs, especially alongside GLP-1 agonists.
Read the reports (what users report 4, common issues 5)
Energy boost from B-vitamins is the most consistently reported benefit. Fat loss without caloric deficit: near-zero consensus benefit.
- Energy boost within 2–4 hours post-injection (attributed to thiamine + dexpanthenol B-vitamins)
- Perceived liver health support, especially in TRT or high-fat diet contexts
- Useful adjunct during GLP-1-induced caloric restriction: may offset energy deficit fatigue
- No reconstitution required: lower barrier than lyophilized peptides
- Fat loss without diet and exercise: near-zero community consensus: multiple experienced users explicitly state "Lipo-C alone does nothing for fat loss"
- Injection site burning and nodule formation with repeated use at same site (especially SC abdomen)
- Fishy body odor (choline → trimethylamine) lasting ~24 hours post-injection, especially at daily dosing
- High non-responder rate: substantial portion of consistent users report zero subjective benefit
- Formulation inconsistency across compounding pharmacies: ingredient profiles differ materially
Both science and community agree: Lipo-C is at best a supportive adjunct requiring a caloric deficit and exercise to produce fat loss. Science confirms component-level mechanisms; community confirms energy benefit but not standalone fat loss. No meaningful divergence in primary conclusion.
Lipo-C Dosage Guide
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 1 mL | 2x/week |
| Moderate | 1 mL | 3x/week |
| Aggressive | 1 mL | Daily |
Lipo-C arrives pre-mixed from the compounding pharmacy. No reconstitution math, no bacteriostatic water, no insulin syringe unit conversions. Draw 1 mL from the vial and inject. That's the whole protocol.
One thing most beginners miss: "Lipo-C" is not a standardized product. Some compounding pharmacies ship a 4-ingredient formula. Others send a 10-ingredient version that adds lidocaine, L-arginine, B6, and B12. Both get labeled Lipo-C. Confirm your exact formulation with your prescriber before comparing notes with anyone else's protocol.
Keep the vial refrigerated at 2 to 8 degrees C. If you see white precipitate (crystallization from cold storage), warm the vial to room temperature and gently roll it. Don't shake. If particulates don't clear after warming, don't inject that vial.
Standard 30 mL vial at 1 mL per injection gives you 30 doses. At 2x/week, that's 15 weeks from one vial, which stretches past the typical 12-week course. Check pharmacy dating; most are labeled for 90-day use after compounding.
Cycling Protocol
Cycling is recommended to allow the body to recalibrate baseline nutrient levels. Many clinics run 12-week courses with a short break before resuming. No receptor desensitization is expected since these are nutrients, not receptor agonists.
Lipo-C components are nutrients (amino acids, vitamins), not receptor agonists: no receptor desensitization occurs. Cycling is recommended to allow metabolic recalibration, assess ongoing need, provide a break from injection site burden, and monitor for cumulative effects (e.g., hypermethioninemia in susceptible individuals). Standard clinic protocol: 12 weeks on, 2 weeks off before resuming.
- Persistent injection site nodules or skin changes that do not resolve between injections
- Fishy body odor that does not resolve within 48 hours of injection (sign of FMO3 impairment or methionine/choline overload)
- Elevated homocysteine (suggests methionine excess) on routine labs
- No perceived benefit after 8 weeks of consistent use with appropriate diet and exercise
Or use the universal Peptide Calculator for any peptide.
Lipo-C Protocols by Goal
Expected: Modest energy support; fat metabolism assistance when combined with caloric deficit and exercise. No meaningful standalone fat loss.
Monitor: Monitor injection sites for nodules. If fishy body odor develops, reduce frequency to 2x/week maximum.
How to Use Lipo-C
- 1Step 1
Remove the Lipo-C vial from the refrigerator 10 to 15 minutes before injection. Let it reach room temperature. Check for clarity; if you see white particles, gently roll the vial between your palms until they dissolve.
- 2Step 2
Clean the vial stopper with an alcohol swab and let it air dry for 10 seconds.
- 3Step 3
Using a 1 mL syringe with a 25 to 27 gauge needle (1 to 1.5 inch for intramuscular, 5/8 inch for subcutaneous), draw the plunger to 1 mL of air and inject the air into the vial. This equalizes pressure.
- 4Invert the vial and draw 1 mL of solution (the full dose)
Pull the syringe to the 1.0 mL mark, which equals the complete per-injection dose containing approximately 50 mg choline, 50 mg L-carnitine, 50 mg inositol, 15 mg methionine, 15 mg thiamine, and 5 mg dexpanthenol.
- 5Tap the syringe barrel to move air bubbles to the top
Push the plunger gently until a small drop appears at the needle tip.
- 6Clean the injection site with alcohol
For intramuscular: inject into the vastus lateralis (outer quad), gluteus, or deltoid at a 90-degree angle. For subcutaneous: pinch skin at the abdomen or outer thigh and insert at a 45-degree angle.
- 7Inject slowly over 5 to 10 seconds
Withdraw the needle and apply gentle pressure with a cotton ball.
- 8Rotate injection sites with each injection
Use a minimum of 7 distinct sites if injecting daily. Mark your rotation to avoid repeating.
- 9Administer in the morning when possible
The B-vitamin energy effect peaks 2 to 4 hours post-injection. Return the vial to the refrigerator immediately after use.
Alternative Routes
No dose difference; 1 mL per injection regardless of route
Quad (vastus lateralis) preferred in community due to fewest adverse reactions. Glute and deltoid also used clinically. 25–27g, 1–1.5 inch needle. Minimal injection site reactions at this route.
Same dose (1 mL); absorption slightly slower than IM but bioavailability near 100% for either route
SC abdomen is common but carries documented higher risk of injection site burning and nodule formation vs IM. 5/8 inch, 25–27g needle. Strictly limit to 1 mL per site injection. Community increasingly disfavors SC abdomen for Lipo-C specifically.
Lipo-C Stacking Protocols
Works With
Most common clinical stack: Lipo-C provides energy support and liver lipotropic coverage during GLP-1-induced caloric restriction. Weight loss telehealth clinics routinely prescribe them together.
1 mL Lipo-C 2–3x/week on non-semaglutide days
Same rationale as semaglutide stack: Lipo-C used as metabolic support adjunct. A telehealth clinic review describes this as the most common Lipo-C combination seen clinically.
1 mL Lipo-C 2x/week; inject on non-tirzepatide days
Complementary fat mobilization mechanisms: AOD targets GH fragment lipolytic pathway; Lipo-C provides lipotropic/mitochondrial support. Common in clinic weight loss stacks.
Both injected as prescribed by clinic; AOD 250–300 mcg SC daily separate from Lipo-C IM injection
Same GLP-1 adjunct rationale as semaglutide. Less common since semaglutide displaced liraglutide in weight management, but still prescribed in some clinic programs.
1 mL Lipo-C 2x/week alongside daily liraglutide
Avoid
Methionine in Lipo-C is a precursor to S-adenosylmethionine (SAMe), which donates methyl groups in serotonin synthesis. Combined with serotonergic drugs, there is a theoretical serotonin syndrome risk, particularly with MAOIs.
Methionine competes with levodopa for neutral amino acid transport across the blood-brain barrier, potentially reducing CNS levodopa bioavailability and worsening Parkinson's disease control.
Methionine affects homocysteine metabolism and potentially clotting parameters. Monitor INR closely if combining.
Estimated Cost
Pricing updated 2026-04-09
Lipo-C Side Effects
The most clinically relevant safety concern with Lipo-C is hepatotoxicity in individuals with pre-existing liver disease. Methionine excess leads to hypermethioninemia, which is directly hepatotoxic. Severe liver disease and bile duct obstruction are contraindications, not precautions. That distinction matters because Lipo-C is sometimes marketed for "liver support," which could mislead someone with actual hepatic pathology into thinking it would help.
Fishy body odor is the side effect that gets the most attention in community discussions. Choline is converted by gut bacteria into trimethylamine (TMA). TMA gets excreted through sweat, breath, and urine. The smell can persist 24 hours post-injection at daily dosing frequency. Individuals with impaired FMO3 enzyme activity (the enzyme that converts TMA to odorless TMAO) are especially susceptible; people with diagnosed trimethylaminuria (TMAU) should avoid Lipo-C entirely. Reducing injection frequency to twice weekly and injecting in the morning are the two most effective mitigations the community has identified.
Injection site reactions are common (>10% of users reporting). Mild pain, redness, and swelling at the injection site are standard for any injectable formulation. A 2021 case report documented something more concerning: localized skin inflammation and lipogranuloma-like nodules from repeated choline injections at the same site. Strict injection site rotation (minimum 7 distinct sites) is required, particularly at daily dosing frequency. Subcutaneous abdominal injection carries higher nodule risk than intramuscular routes per community reports.
Nausea and GI upset occur occasionally, especially when stacking Lipo-C with GLP-1 agonists. The compound GI burden of semaglutide or tirzepatide plus Lipo-C can worsen nausea in susceptible individuals. Separating injection timing by several hours helps.
Increased urination is expected as excess water-soluble B vitamins are cleared renally. This is physiologically normal and not a safety concern in healthy individuals. Active kidney disease changes this calculation; impaired renal clearance of water-soluble vitamins is listed as a contraindication.
Methionine interacts with anticoagulants through homocysteine metabolism. Patients on warfarin should have INR monitored within 2 weeks of starting Lipo-C and monthly thereafter. L-carnitine may reduce the cellular effectiveness of thyroid hormones, which matters for patients on levothyroxine. And methionine, as a SAMe precursor, feeds into serotonin synthesis, creating a theoretical serotonin syndrome risk when combined with MAOIs.
Rare allergic reactions (hives, swelling, difficulty breathing) have been reported. Stop immediately and seek emergency care for any signs of anaphylaxis.
Pregnancy and breastfeeding safety has not been established. Assume contraindicated until data says otherwise.
Common Issues & Solutions
Fishy body odor (choline → TMA): reduce injection frequency to minimum effective dose (2x/week), inject earlier in the day, consider choline-restricted diet on injection days. Individuals with FMO3 enzyme impairment (TMAU) should avoid Lipo-C entirely.
Injection site nodules or hard lumps: confirms repeated injection at same site: implement strict 7-site rotation. Warm vial to room temperature before drawing. Lumps may persist 4–8 weeks after stopping injection at that site.
No perceived benefit after 4–6 weeks: Lipo-C produces no standalone fat loss without caloric deficit. Reassess diet adherence before attributing to formulation. Energy effect may be blunted in B-vitamin-replete individuals.
Crystallization/particulates in vial: refrigerated storage can cause choline or inositol precipitation. Warm vial to room temperature and gently roll (do not shake) before drawing. Do not inject if particulates do not clear.
Nausea or GI upset post-injection: uncommon but reported, especially when stacking with GLP-1 agonists. Separate injection timing by several hours and ensure patient is not dehydrated.
Ask AI about this page
Ask AI for a second opinion on Lipo-C dosing and side effects
Contraindications
- Pregnancy or breastfeeding: safety has not been established
- Known allergy to any component (methionine, inositol, choline, L-carnitine, thiamine, dexpanthenol)
- Severe liver disease or bile duct obstruction
- Homocystinuria or other methionine metabolism disorders
- Trimethylaminuria (TMAU): choline may worsen fishy body odor symptoms
- Active kidney disease: impaired clearance of water-soluble vitamins
Drug Interactions
- Anticoagulants (warfarin): methionine may affect homocysteine levels, potentially influencing clotting parameters; monitor INR
- Thyroid medications (levothyroxine): L-carnitine may reduce the effectiveness of thyroid hormones at the cellular level
- Diabetes medications (insulin, sulfonylureas): potential additive effect on blood sugar management; monitor glucose levels
- Methotrexate and other folate antagonists: methionine is involved in the folate-methionine cycle and interactions are possible
- Acetylcholinesterase inhibitors: additional choline may have additive cholinergic effects
- Methionine in Lipo-C is a precursor to S-adenosylmethionine (SAMe), which donates methyl groups in serotonin synthesis. Combined with serotonergic drugs, there is a theoretical serotonin syndrome risk: particularly with MAOIs.
- Warfarin / Anticoagulants
Product Quality
Compounding pharmacy quality varies significantly. Two dominant formulations (a 4-ingredient version and a 10-ingredient version adding lidocaine, L-arginine, B6, B12) are pharmacologically distinct but both sold under the "Lipo-C" name. No FDA batch testing or efficacy review applies to 503A compounded products.
- Verify your pharmacy holds a valid 503A compounding license with your state pharmacy board
- A batch Certificate of Analysis (CoA) confirms ingredient concentrations in a compounded vial
- Inspect vial for clarity before each injection: warm to room temperature if crystallization (white precipitate) is observed; do not inject if particulates persist
- Confirm your exact formulation ingredients and concentrations with your prescriber: "Lipo-C" is not a standardized product
- Avoid gray-market online sources: no non-prescription injectable Lipo-C is legitimate in the US
Recommended Monitoring
| Test | When | Target |
|---|---|---|
| Liver function panel (ALT, AST, bilirubin) | Baseline; repeat at 12 weeks if history of liver disease | ALT/AST within 2x upper limit of normal |
| INR (if on warfarin) | Within 2 weeks of starting Lipo-C; monthly thereafter | Therapeutic range per prescriber (typically 2.0–3.0 for AF; 2.5–3.5 for mechanical valves) |
| Body weight and waist circumference | Baseline; every 4 weeks | Not listed |
| Injection site inspection | Each injection; formal assessment at weeks 4 and 8 | Not listed |
Methionine excess can cause hypermethioninemia and hepatotoxicity in individuals with impaired liver function or bile duct obstruction. Relevant contraindication group.
Methionine affects homocysteine metabolism and may influence clotting parameters in anticoagulant-dependent patients.
Primary outcome assessment: distinguishes Lipo-C contribution from concurrent diet/GLP-1 effects.
2021 case report documented lipogranuloma-like nodules from repeated choline injections at same site. Strict rotation must be maintained.
Lipo-C Before and After
Initial adjustment period. Some users report a mild increase in energy levels from the B-vitamin components. No significant body composition changes expected yet. Injection site tenderness may occur as the body adapts.
Gradual improvements in energy and exercise tolerance. When combined with a calorie deficit and regular exercise, early fat loss may become noticeable. Liver fat processing may improve based on the lipotropic effects of MIC.
Continued support for fat metabolism. Users following a structured diet and exercise plan may observe measurable changes in body composition. The L-Carnitine component supports ongoing fatty acid oxidation during exercise.
A short break of 2 weeks is typically recommended before resuming. Long-term use is generally considered safe given the nutrient-based formulation. Sustained results depend entirely on maintaining healthy lifestyle habits.
What to Expect
Days 1 through 7: Thiamine and dexpanthenol absorb rapidly after intramuscular or subcutaneous injection. B-vitamin cofactor replenishment starts within hours. The most consistently reported early effect is an energy boost within 2 to 4 hours of the first injection. Some users notice a warm sensation or mild flushing at the injection site. Injection site soreness and mild burning at subcutaneous sites are common. Fishy body odor from choline may appear from day one in susceptible individuals. No body composition changes are expected this early.
Weeks 2 through 4: Choline and methionine begin supporting hepatic phosphatidylcholine synthesis and VLDL-mediated fat export from the liver. L-carnitine starts contributing to mitochondrial fatty acid oxidation, particularly during exercise. Users maintaining a caloric deficit and exercise program report improved exercise endurance and recovery. Sedentary users without a deficit report minimal response. Fishy odor becomes more consistent at 3x/week or daily dosing. Injection site nodule risk increases with repeated use at the same location.
Weeks 4 through 8: L-carnitine data from the 2025 umbrella meta-analysis [1] shows clinically meaningful but modest weight reduction (effect size -1.11 kg) at 8 to 30 weeks with 150 to 4,000 mg/day oral dosing. The injectable route bypasses first-pass metabolism but equivalent fat loss data specific to intramuscular or subcutaneous delivery is not established. Users in structured programs report incremental improvement over diet alone. Users without a caloric deficit report minimal to no fat loss. Energy benefits persist. Formulation quality issues (crystallization, potency drift) may surface; site rotation discipline remains critical.
Weeks 8 through 12: Component-level benefits are expected to sustain with continued use. No tolerance develops because these are nutrients, not receptor agonists. Most users who report benefit maintain it through the full 12 weeks. Some reduce to 2x/week maintenance after initial response. A two-week break before repeating the course is standard clinic protocol. No new side effects typically emerge at this stage, but cumulative injection site burden should be assessed.
Detailed Timeline: Science vs Community
Thiamine and dexpanthenol (provitamin B5) absorbed rapidly IM/SC; B-vitamin cofactor replenishment begins within hours. No body composition change expected.
Noticeable energy boost within 2–4 hours of first injection is the most consistently reported early effect. Some users report warm sensation or mild flushing at injection site.
Choline and methionine support hepatic phosphatidylcholine synthesis and VLDL-mediated fat export. L-carnitine begins supporting mitochondrial fatty acid oxidation, especially during exercise. No population-level fat loss expected without caloric deficit.
Improved exercise endurance and recovery reported by users maintaining caloric deficit and exercise program. Minimal response in sedentary users.
L-carnitine RCT data (PMID 40298161 umbrella meta-analysis) shows clinically significant but modest weight reduction (−1.11 kg ES) at 8–30 weeks with 150–4,000 mg/day oral. Injectable route bypasses first-pass but equivalent fat loss data specific to IM/SC route is not established.
Users in structured diet and exercise programs report incremental improvement over diet alone. Users without caloric deficit report minimal to no fat loss. Energy benefit persists.
Component-level benefits expected to be sustained with continued use. No tolerance development expected for nutrient-based compounds.
Most users who report benefit maintain it through 12 weeks. Some reduce to 2x/week maintenance after initial response. Two-week break typically observed before repeating course per clinic protocol.
Pharmacokinetics
Source: No single half-life applies to the blend. L-Carnitine plasma half-life is ~4-6 hours; B vitamins run ~2-6 hours.
Is Lipo-C Legal?
Lipo-C is not FDA-approved. It is a 503A compounded product, meaning it is mixed by licensed compounding pharmacies on a per-patient prescription basis. No FDA review of safety, efficacy, or manufacturing consistency applies to 503A compounds. The FDA has authority over compounding pharmacies but does not pre-approve individual formulations.
Lipo-C requires a prescription in the United States. There is no legitimate non-prescription injectable Lipo-C product on the US market. Any source selling it without a prescription is operating outside the regulated framework.
WADA status: individual components (L-carnitine, B vitamins, amino acids) are not currently prohibited by the World Anti-Doping Agency. Athletes should verify current status on the WADA prohibited list before use, as classifications change annually.
Compounding pharmacy quality varies. A valid state 503A license and a batch-specific Certificate of Analysis (CoA) are the main markers of quality. Two pharmacologically distinct formulations are sold under the "Lipo-C" name.
This content is for informational purposes only. It does not constitute medical advice. Consult a licensed healthcare provider before starting any injectable protocol.
Evidence grade: No human studies found (Peptide Evidence Gap, October 2026)
Who Should Consider Lipo-C
- Adults pursuing weight loss alongside diet and exercise programs
- Individuals with sluggish metabolism seeking nutritional support
- Patients in medically supervised weight management clinics
- Adults looking for a non-hormonal adjunct to fat loss protocols
- Individuals with suboptimal dietary intake of methionine, choline, or B vitamins
Related Peptides
What Changed for Lipo-C
Peptide Schedule Research TeamReviewed Apr 7, 20265 Citations
References
- [1]The effect of L-Carnitine supplementation on obesity indices: an umbrella meta-analysis (Hamedi-Kalajahi et al., Int J Vitam Nutr Res 2025) (opens in a new tab)PubMed (opens in a new tab)PubMed
Additional References
- Effects of L-carnitine supplementation on weight loss and body composition: A systematic review and meta-analysis of 37 RCTs (Clin Nutr ESPEN 2020) (opens in a new tab)PubMed 32359762PubMed
- The effect of (L-)carnitine on weight loss in adults: a systematic review and meta-analysis of randomized controlled trials (Obes Rev 2016) (opens in a new tab)PubMed 27335245PubMed
- The effect of choline and myo-inositol on liver and carcass fat levels in aerobically trained rats (Int J Sport Nutr 1995) (opens in a new tab)PubMed 7751073PubMed
- Inositol and choline levels in the diet and neutral lipid hepatic content of lactating rat (Int J Vitam Nutr Res 1989) (opens in a new tab)PubMed 2777503PubMed
Related Tools
Storage & Stability
Frequently Asked Questions
How popular is Lipo-C?
Popular. A popularity tier (hot, popular, emerging or niche), based on search volume and community activity.
Reddit: Moderate. Community mentions on Reddit: Moderate: appears in r/peptides, r/WeightLoss, r/GLP1. Open r/peptides (opens in a new tab).
15 papers on PubMed, the US library of medical research. Search them on PubMed (opens in a new tab).
High search interest. A band for how often people search Google for the name each month.
These come from this site's peptide records. They are not live counts.